Abstract: A content addressable memory system, method and computer program product is described. The memory system comprises a location addressable store having data identified by location and multiple levels of content addressable stores each holding ternary content words. The content words are associated with references to data in the location addressable store and the content words containing at least one next entry bit for sorting content words in a physical ordered sequence to create content ordered memory. The content store levels might be implemented using different technologies that have different performance, capacity, and cost attributes. The memory system includes a content based cache for improved performance and a content addressable memory management unit for managing memory access operations and virtual memory addressing.

Abstract: Methods for treating the animal central nervous system for the effects of traumatic brain injury. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient suffering from traumatic brain injury. The effective amount of DFO is delivered directly to the patient's central nervous system for treating the traumatic brain injury.

Abstract: Methods for treating the animal central nervous system against the effects of spinal cord injury, including associated cognitive, behavioral and physical impairments. Effective amounts of therapeutic agents are administered to the upper third of the patient's nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of a therapeutic agent is the iron chelator deferoxamine (DFO).

Abstract: Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of progressive supranuclear palsy. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with, progressive supranuclear palsy. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating the progressive supranuclear palsy.

Abstract: A content addressable memory system, method and computer program product is described. The memory system comprises a location addressable store having data identified by location and multiple levels of content addressable stores each holding ternary content words. The content words are associated with references to data in the location addressable store and the content words containing at least one next entry bit for sorting content words in a physical ordered sequence to create content ordered memory. The content store levels might be implemented using different technologies that have different performance, capacity, and cost attributes. The memory system includes a content based cache for improved performance and a content addressable memory management unit for managing memory access operations and virtual memory addressing.

Abstract: Automatically create abstractions of large sets of data and then probabilistic inferences based on the abstractions. The probabilistic inference is derived from the logical hierarchy using Bayesian statistics to infer a probabilistic event based upon a characteristic of the data in a hierarchy of synthetic events. The logical hierarchy of a set of a plurality of synthetic events is related by at least one characteristic of data is built by accessing a first set of data. The first set of data is organized based on a first characteristic. A second set of data different than the first set of data is accessed. A second set of data based is organized based on a second characteristic. The first characteristic and the second characteristic are processed to generate a synthetic event. The synthetic event is a third set of data representing a result of a mathematical computation defined by an operation S(p1)==>F(p2).

Abstract: A system comprises a hashing logic, which executes instructions to convert raw data into a first logical address and payload data, where the first logical address describes metadata about the payload data. A hardware translation unit executes instructions to translate the first logical address into a first physical address on a storage device. A hardware load/storage unit stores the first logical address and the payload data at the first physical address on the storage device. A content addressable store is associated with a reference to the logical addressed data in this location addressable high dimensional store, where the content addressable store is searched for the desired content word using at least one temporal attribute to retrieve the corresponding references with low latency. A hardware exclusive OR (XOR) unit compares two logical address vectors to derive a Hamming distance between the two logical address vectors.

Abstract: A customer support application provides screen sharing of the user's computing device with a remote customer support agent, thereby enabling the customer support agent to view the content displayed on the user's device. At least a portion of the content displayed on the user's device may contain sensitive information. Coordinates corresponding to the content displayed on the user's device may be obtained and the portion of the display corresponding to the coordinates may be obscured from the remote customer support agent.

Abstract: The gasification of a carbonaceous material includes receiving a volume of feedstock, supplying thermal energy to the volume of feedstock to convert at least a portion of the volume of feedstock to at least one pyrolysis reaction product via at least one pyrolysis reaction, super-heating the at least one pyrolysis reaction product, providing a volume of super-heated steam, mixing the volume of super-heated steam with the super-heated at least one pyrolysis reaction product and converting at least a portion of at least one reformed product to at least one synthesis gas product via at least one water-gas-shift reaction.

Abstract: System and Method for Real Time Updates of Progress of Medical Procedures. This invention enables several users of a provider such as doctors and nurses to send one-way real time messages about the progress of a procedure to multiple recipients. As sessions are identified by a random key, users are not required to divulge personal information or set up accounts to access the system. When new messages are posted to a session, users may optionally choose to be notified by text messages or emails. Messages are selected from templates that are specific to the provider. Messages may be sent from and received on multiple network connected computers, laptops, mobile ort medical devices at the same time.

Abstract: The gasification of a carbonaceous material includes receiving a volume of feedstock, supplying thermal energy to the volume of feedstock to convert at least a portion of the volume of feedstock to at least one pyrolysis reaction product via at least one pyrolysis reaction, super-heating the at least one pyrolysis reaction product, providing a volume of super-heated steam, mixing the volume of super-heated steam with the super-heated at least one pyrolysis reaction product and converting at least a portion of at least one reformed product to at least one synthesis gas product via at least one water-gas-shift reaction.

Abstract: Pharmaceutical compositions for treating and/or pre-treating or preconditioning the animal central nervous system against the effects of Alzheimer's Disease including the associated neurodegeneration and cognitive, behavioral and physical impairments. In one embodiment, an effective dose of deferoxamine (DFO) is administered to the upper one-third of the subject patient's nasal cavity to effectively bypass the blood-brain barrier, thereby allowing application of the DFO dose directly to the central nervous system.

Abstract: Methods for treating the animal central nervous system against the effects of stoke, including associated cognitive, behavioral and physical impairments. Effective amounts of therapeutic agents are administered to the upper third of the stroke patient's nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of a therapeutic agent is the iron chelator deferoxamine (DFO).

Abstract: Described herein are systems and methods for automatically selecting a content provider for delivery of content for consumption by a user. Various selection data such as cost, subscription plan, and so forth are gathered and a weighting profile is applied to generate a total weight by content provider. The total weight by content provider may be used to select one content provider from another for delivery of a particular piece of content.

Abstract: A system for matching entities comprising a contributor parameter system operating on a processor and configured to generate a plurality of contributor selection controls, each contributor selection control associated with one or more user-selectable parameters. A recipient parameter system operating on the processor and configured to generate a plurality of recipient input controls, each recipient input control associated with one or more user-selectable parameters. A recipient bundling system operating on the processor and configured to receive the user-selected parameters from the contributor selection controls and the user-selected parameters from the recipient input controls and to select a plurality of recipients as a function of the user-selected parameters from the contributor selection controls and the user-selected parameters from the recipient input controls.

Abstract: A system for analyzing data, comprising a metrics data system operating on a processor and configured to generate a user prompt that allows a user to interactively provide metrics data associated with an organization. A metrics display function system operating on the processor and configured to generate a user prompt that allows a user to interactively select or modify a display process that is to be applied to the metrics data. A metrics analytics function system operating on the processor and configured to generate a user prompt that allows a user to interactively select or modify a data analysis function that is to be applied to the metrics data.

Abstract: An application may be installed on a user device. Installing the application may include receiving and storing an executable application, a plugin, and an application manifest. The application manifest may include a path corresponding to the plugin and one or more rules associated with the plugin. A webpage may be requested from the web server. The webpage may be parsed to determine that the webpage includes an instruction to use the plugin. It may be determined that the application includes the plugin. The path corresponding to the plugin may be obtained from the application manifest. The webpage may be presented using the plugin.

Abstract: Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of Huntington's disease. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with Huntington's disease. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating Huntingon's disease.

Abstract: Methods for preconditioning, treating and/or providing neuroprotection to the animal central nervous system against the effects of neurodegeneration caused by iron accumulation in the brain. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. An examplary therapeutic agent is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for or diagnosed with neurodegeneration caused by iron accumulation in the brain. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating neurodegeneration caused by iron accumulation in the brain.

Abstract: Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of Lewy body syndrome. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with, Lewy body syndrome. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating the Lewy body syndrome.